Two commercial Bacillus-based probiotics , Sanolife PRO-W (water application) and Sanolife PRO-2 (feed application) , were evaluated for their effects on growth performance, microbial colonisation, and disease resistance in Pacific whiteleg shrimp ( Penaeus vannamei ). Specific pathogen-free postlarvae were reared for 45 days under five treatments: control, PRO-W at 4 or 10 mg/200 L biweekly, and PRO-2 at 1 or 5 g/kg feed daily (n = 4 tanks per treatment; 80 shrimp per tank). Following the growth trial, shrimp were challenged with either Vibrio parahaemolyticus (VpAHPND strain) or Photobacterium damselae subsp. damselae at 10⁵ CFU/mL for 7 days.
Both probiotics significantly improved survival (89.69–94.38% vs . 84.38% in controls), body weight (1.71–1.93 g vs . 1.54 g; Fig. 1), and feed conversion ratio (1.16–1.28 vs . 1.55). Probiotic treatments reduced hepatopancreatic and intestinal Vibrio counts by 35–65%, while increasing beneficial Bacillus populations 5- to 11-fold, with dominant species shifting to B. licheniformis , B. subtilis , and B. pumilus in probiotic-treated groups.
During disease challenges, both probiotics significantly improved survival against P. damselae infection (57.5–62.5% vs . 42.5% in controls; Fig. 2), with normal hepatopancreatic histopathology in probiotic groups. In contrast, neither product provided significant protection against VpAHPND (35–40% vs. 30% in controls), and hepatopancreatic damage was observed across all groups.
These findings confirm that Sanolife PRO-W and PRO-2 enhance shrimp production performance through microbial modulation and confer meaningful protection against infection-driven pathogens. However, additional management strategies are required to combat toxin-mediated diseases such as AHPND (acute hepatopancreatic necrosis disease).